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A B S T R A C T
Objectives: Human papillomavirus is themain causative agent for cervical cancer. However, few data are
available about HPV prevalence in Kazakhstan. The aims of this study were to genotype HPV DNA in Pap
smear samples of women to determine prevalence of carcinogenic HPV types in Astana, Kazakhstan and
to analyze the association between HPV positivity and the cytology results of patient samples.
Methods: Pap smear materials were obtained from 140 patients aged 18-59, who visited the outpatient
gynecological clinic. Microscopic examination was done to detect dysplasia, and HPV genotyping was
done using real-time multiplex PCR.
Results: HPV testing showed that among 61 HPV positive patients, themost prevalent types were 16 and
18. Microscopic examination showed that 79% of the samples had normal cytology, while 13% had CIN
grade I, 5% had CIN grade II, and 3% had CIN grade III. The analysis revealed that 12% of the samples had
CIN cytology and presence of HPV. Approximately 31% had HPV without cervical dysplasia, while 8% of
samples were CIN positive without HPV infection. A statistically signiﬁcant relationship between HPV
16 and HPV 33 positive samples and CIN grade II and III was found.
Conclusions: Overall, this study will help to strengthen and guide health policy implementation of
primary and secondary cervical cancer prevention strategies in Kazakhstan.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Background
Cervical cancer is the third most diagnosed type of cancer and
the fourth leading cause of death in women
worldwide1. Approximately 99% of all cervical cancer cases have
been linked to Human papillomavirus (HPV) infection, which has
also been associated with other anogenital cancers (anus, vulva,
vagina and penis), and head and neck cancers2. HPV is a small non
enveloped double-stranded DNA virus of Papillomaviridae
family3. Of the more than 100 HPV types, 15 (16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) were identiﬁed as high risk
(HR) due to their strong correlation to cancers of the anogenital
region4. HPV types 16 and 18 are responsible for about 70% of all
cervical cancer cases worldwide, while other HPV types like 31, 33,* Corresponding author. Nazarbayev University School of Medicine (NUSOM),
53 KabanbayBatyr Ave., Astana, Republic of Kazakhstan, 010000.
E-mail address: azliyati.azizan@nu.edu.kz (A. Azizan).
http://dx.doi.org/10.1016/j.ijid.2016.11.410
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).35, 45, 52 and 58 account for 20% of cervical cancers in the
world5. Screening for cervical cancer with the Papanicolaou
cytology technique, or Pap smear test for short, has become
widely accepted. The Pap smear test is aimed to detect cervical
intraepithelial neoplasia (CIN), which is a premalignant transfor-
mation in the cervix. Additionally, HPV DNA testing for HR-HPV
types is also recommended to improve the accuracy of screening
for cervical cancer, and to increase chances for recovery6.
Current estimates for Kazakhstan indicate that every year 2,789
women are diagnosed with cervical cancer and 982 die from the
disease2. Cervical cancer in Kazakhstan ranks as the second most
frequent cancer among women and the ﬁrst most frequent cancer
among women between 15 and 44 years of age with the incidence
of 32.82. However, there is still lack of sufﬁcient information about
the prevalence of HR-HPV types in Kazakhstan. Having more
information about the types of HPV strains that are prevalent in
patients with abnormal cytology and hence are at high risk for
developing cervical cancer can provide guidance regarding
preventative measures against cervical cancer. This pilot studyciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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the primary objective was to determine the most prevalent HPV
types in Astana, Kazakhstan by genotyping HPV DNA in Pap smear
samples of women that are at risk to develop cervical cancer. The
second objective of this study was to analyze the association
between HPV positivity and the cytology results of patient
samples. This also serves as a feasibility study that will form the
basis for a larger study. Given the high incidence of cervical and
other HPV associated cancers in Kazakhstan and the Central Asian
countries, ﬁndings from such studies could contribute toward
informing relevant policies related to screening and preventative
vaccination and other public health HPV programs in the region.
2. Methods
2.1. Study population and sample collection
The total number of patients in this study was 140 women of
ages 18 – 59 years. The samples were collected as part of a
screening procedure, called Pap smear, from all patients who
attended the gynaecologist’s ofﬁce at University Medical Center
(UMC), Astana, in the period from December, 2015 to April,
2016. The samples were collected in two sets in order to do
microscopic analysis for abnormal cytology and for HPV DNA
genotyping. The sample collection and analysis (microscopy and
RT-PCR) were done on the same day.
2.2. Ethical consideration
The Nazarbayev University Ethical Committee (IREC) granted
exemption from IREC review for this study. Patient conﬁdentiality
was maintained whereby speciﬁc patient information (including
name, contact and other sensitive personal information) was only
accessible to the clinicians, and samples were number-letter coded
to the investigators involved to conduct the protocols proposed for
the study. Patient conﬁdentiality was maintained throughout, and
after completion of the study.
2.3. HPV DNA genotyping and cytological examination of samples
For HPV genotyping, real timemultiplex PCRmethodology using
the speciﬁc PCR kit were used, following manufacturer’s instruc-
tions (https://vector-best.ru/en/publ/list/maket_hpv.pdf - www.
vector-best.ru). The laboratory method is based on simultaneous
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Figure 1. Distribution of HPV types among 61 HR-HPV positive patients, tested in Asta
Abbreviations
HPV = Human papillomavirus; HR-HPV = high risk HPV types.real-time multiplex PCR of HPV-speciﬁc DNA fragments and a
noncompetitive internal control. The real time PCR instrumentation
used for the assay is the CFX 96 Real -Time PCR (BIO-RAD).
Microscopic examination of Pap smear samples was also performed
using standard UMC hospital protocols to reveal cytological
abnormalities7.
2.4. Statistical analysis
All statistical analysis for this study was done with STATA
13.0 software. Simple statistical analysis such as determination of
means, standard deviation, p-value, and odds ratio, was done for
descriptive purposes. The association between age, HPV positivity
status, and cytological pathology was analyzed with logistic
regression.
3. Results
3.1. Prevalence of HPV types among positive samples
Twelve HPVs, which are HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58 and 59, genotypes were detected in our study samples using
real-time PCR. Out of 140 samples analyzed by HPV genotyping,
HPVDNA could be detected in 61 of samples (43.6% of total), and all
12 HPV genotypes could be identiﬁed collectively among these
HPV positive samples. HPV DNA genotyping with real-time PCR
showed that among 61 HPV positive samples, the most prevalent
types detected were HPV 16 (18.4%) and HPV 18 (9.22%), followed
by HPV types 33, 51 and 52 (nearly 5% each) (Figure 1). HPV types
59, 39, 31, 45, and 58 were found in at least 2% of the total amount
of samples, while only about 1% or less of positive samples hadHPV
types 35 and 56.
3.2. Variation of cytology results among different age groups
The results of cytological examination and of HPV DNA
genotyping with age distribution of patients are shown in
Table 1. The age range of patients was from 18 to 59 years old,
with a mean age of 33.5  9.51 years (95% conﬁdence interval (CI)
31.9 – 35.1 years). Among 140 cytology samples, 28were identiﬁed as
CIN grade 1, 2 or 3. The age group of 26-36 years had the highest
number of HPV and CIN positive patients (Table 1). Regression
analysis did not show statistically signiﬁcant association between age
and HPV positive status (p = 0.290). The results of Pap smear testna, Kazakhstan
Table 1
Age distribution among 140 patients with HPV and CIN
Age (years) N women HPV
positive
CIN
positive
OR 95% CI
N % N %*
18-25 23 8 34.7 2 8.70 0.5 0.045 –5.51
26-36 76 38 50.0 17 2.24 1.25 0.27 – 6.5
37-47 25 9 36.0 5 20.0 1.37 0.14 – 14.5
48-59 16 6 37.5 4 25.0 1.33 0.10 – 18.0
Total 140 61 43.6 28 20.0
Abbreviations: HPV=Human papillomavirus; CIN=Cervical intraepithelial neopla-
sia; OR=odds ratio; CI = conﬁdence interval; * - percentage in this age group
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Figure 2. Representation of cytological examination among 140 tested women
Abbreviations
CIN = Cervical intraepithelial neoplasia.
Table 2
Association between HPV type and grade dysplasia
HPV type Characteristic
associated
P value 95% CI
16 CIN 2 0.043 1.08 - 137
CIN 3 <0.005 2.48x105 – 9.72x107
33 CIN 2 <0.005 8.52 - 1686
CIN 3 <0.005 9.81x105 – 5.34x108
Abbreviations: HPV=Human papillomavirus; CIN=Cervical intraepithelial neopla-
sia; OR=odds ratio; CI = conﬁdence interval
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5% had CIN 2, and nearly 3% had grade 3 CIN, while 79% of samples did
not have abnormal cytology (Figure 2).
3.3. Correlation between HPV and CIN in positive samples
The proportion of patients who were positive for both HPV and
CIN was 12% (Figure 3) with the age range from 23 to 42 years.
Patients who had only CIN without HPV infection constitute 8% of
all patients, and the age range of CIN only positive patients was
from 30 to 59 years. One third of the patients (age 18-57 years) had
positive HPV test results but normal cytology from Pap smear. The
remaining samples were negative for CIN and HPV. Logistic
regression analysis showed statistically signiﬁcant association
between HPV types 16 and 33 and CIN grades 2 and 3 (Table 2).
4. Discussion
Our ﬁndings demonstrate that the most prevalent types of HR-
HPV among 61 patients (43.6%) who appeared to be HPV positive,
[(Figure_3)TD$FIG]Figure 3. Predominance of HPV and CIN among 140 women tested at UMC, Astana,
Kazakhstan.are HPV 16 (18.4%) and 18 (9.22%), followed by HPV 33, 51, and
52. It is common practice to do both genotyping and microscopic
examination in cervical cancer screening both in Western
countries and in many Central Asian countries. However, from
Kazakhstan, only one study has been published regarding the
analysis of both genotyping and Pap smear samples from patients.
That study detected total HPV high-risk infection in 26% of the
population tested, with the dominating type being HPV 16
(10.7%)8. The prevalence of HPV 18 and 33 reported by this study
was much smaller (3.61% and 1.25% respectively), though with
their much larger sample size, this ﬁnding may be a more accurate
reﬂection of prevalence for this region of Kazakhstan. Furthermore,
epidemiologic studies worldwide show that HR-HPV types 16 and
18 are predominantly found in cervical cancer cases as well as in
low- and high- grade cervical lesions (CIN 1, 2, 3) 9–11. In addition to
total prevalence of HR-HPV types, association between age and
HPV positive status was analysed because some studies showed
that the peak of HPV positivity usually occurs in women under age
356,12,13. Although in our study we were able to observe that the
majority of HPV positive patients were in the age range from 26 to
36, we did not ﬁnd statistically signiﬁcant correlation (with a p-
value = 0.290) between age and having HPV infection. Most
probably this can be explained by the fact that the sample size
of 140 patients in our study was too small since an estimated
minimum sample size of 189 is required in order to obtain the
power to equal 0.8.
Fully supported by the government of Kazakhstan, the Pap
smear test is recommended for women of reproductive age at 5-
year intervals as a screening procedure for early detection of
preventable cancers14. The results obtained in this study showed
that 20% of tested women had CIN of grades 1 (13.5%), 2 (4.96%),
and 3 (2.84%). After evaluation of the data we could see that 12% of
participants had both cervical dysplasia and HPV infection.
However, it is known that the Pap smear test has quite high
false-negatives rate15, which suggests that some of the HPV
positive patients (31%) with normal cytology should be monitored
for a certain time period. Monitoring HPV positive patients is
necessary to see if the infection will be cleared by immunity in a 1-
2 year period16, or to detect abnormal cell proliferation at early
stages and to start treatment. Clearance of the infection probably
can also explain the fact that 8% of the patients in this study had
dysplasia but not HPV infection. Statistical analysis showed that
there is a statistically signiﬁcant association between having HPV
type 16 and CIN2 and CIN3, as well as being HPV type 33 positive
and having CIN2 and 3 (Table 2). In these cases, the progression to a
higher-grade neoplasia can be rationalized not only by the
presence of HR-HPV infection, but also by persistence of the
infection for a longer period of time. Persistence of the infection
indicates longer exposure to carcinogenic proteins of HPV such as
E6/E7, thus, transformation of normal basal cells to a higher grade
of cervical neoplasia as well as to invasive cervical cancer17,18.
There are several limitations in this study. First, because of
constraints on patient availability, the sample size was smaller
than the estimated number of participants required for obtaining
the results with the power of 0.8. Second, not all samples selected
L. Niyazmetova et al. / International Journal of Infectious Diseases 54 (2017) 85–8888for HPV DNA genotyping had abnormal cytology, which is a
signiﬁcant barrier for ﬁnding true association between the HPV
type and cervical dysplasia. Third, the complete demographic data
and clinical records of all patients were not available due to the
unwillingness of some patients to provide personal information
thatmay be relevant to the study. The suggestion for future studies
is to increase the sample size and to perform the study in different
parts of the country. Another option is to perform pooled analysis
from the whole country as was done in a 2012 study in China and
Europe where the prevalence of HR-HPV and CIN was determined
with meta-analysis18,19. One signiﬁcant ﬁnding from our study is
that HPVDNA could be detected in Pap smear normal samples; this
suggests that the HPV genotyping assay can be a valuable addition
to the Pap smear test as effective and more thorough screening
methodologies. Interventions provided to these early infections
could potentially prevent progression to HPV-related cancers.
5. Conclusion
Overall, this pilot study was important not only to obtain
more data regarding HPV prevalence among Kazakhstan women
and to analyze the correlation between certain HPV types and
cervical dysplasia, but also to provide the basis for future
studies. In conclusion, having a well-informed understanding of
the association of HPV infection and associated cancer could
enhance the public’s acceptance of screening and intervention
programs to reduce morbidity and mortality due to HPV
infection. Speciﬁcally, having a deﬁnitive knowledge regarding
which strain is prevalent in Kazakhstan will provide guidance as
to the best and most cost-effective choice of vaccine for
protection of the population against HPV. The overall goal is
to work toward informing public policy in terms of best
practices that should be adopted with regard to screening and
vaccination preventative programs that would result in signiﬁ-
cant reduction in the incidence and prevalence of cervical and
other cancer types associated with HPV infection.
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